Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that stimulates the pituitary gland to produce and release growth hormone (GH). The native GHRH peptide has a very short half-life of a few minutes, limiting its clinical utility. CJC-1295 was engineered to extend this duration through a process called Drug Affinity Complex (DAC) technology, in which the peptide binds covalently to albumin in the bloodstream, resulting in a half-life of approximately 6–8 days. This allows for weekly or bi-weekly dosing while maintaining consistent GHRH signaling.
Clinical Research
This phase II clinical trial — one of the few human studies of CJC-1295 — enrolled healthy adults aged 21–61. Single and multiple doses of CJC-1295 (with DAC) produced dose-dependent increases in mean GH concentrations (2–10 fold above baseline) and IGF-1 levels (1.5–3 fold increases), with effects sustained for 6 days after a single injection. The compound was generally well-tolerated, with facial flushing and transient injection site reactions as the most common adverse events.
Growth hormone secretion declines approximately 14% per decade after peak levels in young adulthood, with a parallel decline in IGF-1. This age-associated somatopause is associated with changes in body composition (increased visceral adiposity, decreased lean mass), bone density, and energy levels — providing the theoretical rationale for GH secretagogue research in older adults.
CJC-1295 Without DAC (Modified GRF 1-29)
A related compound sometimes called CJC-1295 without DAC (or Mod GRF 1-29) lacks the albumin-binding moiety and has a shorter duration of action — more similar to a GH pulse stimulant. It is typically combined with a GHRP (growth hormone-releasing peptide) such as ipamorelin to produce synergistic GH release while preserving the pulsatile nature of physiological GH secretion, as opposed to continuous stimulation.
Areas of Research Interest
- Body composition — lean mass support and adiposity management
- Bone mineral density in the context of age-related decline
- Recovery and collagen synthesis (indirectly via IGF-1)
- Sleep quality (GH is secreted predominantly during slow-wave sleep)
Considerations and Limitations
While the 2006 Teichman trial demonstrated pharmacological GH and IGF-1 elevation, clinical outcome data — changes in body composition, function, quality of life — were not its focus. Long-term safety data from human trials are limited. GH pathway stimulation is contraindicated in patients with active malignancy and requires careful evaluation in patients with diabetes or pre-diabetes, as GH can cause insulin resistance. Any CJC-1295 protocol at a licensed telemedicine practice begins with a thorough evaluation including relevant labs and a detailed medical history review.
References
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Veldhuis JD, et al. Somatotropic Axis in Aging. Endocr Rev. 2013;34(4):556-595.
- Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557-68.
- FDA Drug Database. CJC-1295 is not FDA-approved; available only as a compounded preparation from licensed 503A pharmacies with a valid prescription.